Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups

Fig. 1

Study population and study design. We collected 166 TMAs containing 19,039 cores from 10,005 patients. Of these, 15 TMAs containing 1346 cores were selected as the training set and these were used to develop an automated scoring protocol that was validated against corresponding computer-assisted visual (CAV) scores. Ultimately, this protocol was applied to the scoring of all 166 TMAs. Following automated scoring, all cores that failed our priori defined quality control checks (including total nuclei count >50 and <15,000, and KI67 score = 100 %) were excluded (N = 946 patients). For the purpose of survival analyses, all subjects with missing follow-up/survival data were also excluded (N = 971 patients). As a result, a total of 8088 patients were used in the survival analysis involving automated KI67 score. Furthermore, based on a subset of patients (N = 2440) with pathologists’ KI67 scores in addition to the automated KI67 scores, we extrapolated a visual from an automated cut-off point and used this to compare the prognostic performance of visual and automated KI67 scores in breast cancer. QC quality control, TMA tissue microarray

Back to article page